Outrage against PBMs was on full display when 400 pharmacy professionals in Kansas shuttered their businesses and petitioned ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report (Second Report) stemming from its investigation into pharmacy benefit ...
Walgreens-Boots Alliance struggles with margin compression, competition, and financial risks. Learn why these challenges make ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM space, including those from the FTC. In this Special Edition of the ...
For years PBMs have been assailed by pharma companies and Congress, and the new Trump administration looks likely to keep up the barrage.
during his first term the FTC allowed consolidation to occur in the industry in the late 2010s. And despite the anti-PBM rhetoric in Trump’s White House, practically nothing of substance was ...
CVS Health reported $1.6 billion in profit for the fourth quarter, down from a $2 billion haul a year ago, according to its ...
Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries ...
The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...
The parents of Cole Schmidtknecht, 22, are suing Walgreens and OptumRx, a subsidiary of UnitedHealth Group, over the Wisconsin man's death in 2024.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results